Rubens, Jami R., Lewandrowski, Kent B., Kopans, Daniel B., Koerner, Frederick C., Hall, Deborah A., and McCarthy, Kathleen A.
Medullary carcinoma of the breast is a fairly rare subtype of infiltrating ductal carcinoma with a more favorable prognosis than the more common forms of invasive breast cancer. However, it seems likely that medullary carcinoma is overdiagnosed, leading to less aggressive treatment than is warranted for the cancer that really exists. A review of all breast cancer cases diagnosed at Massachusetts General Hospital in Boston over a 10-year period is provided. Tumors were classified as typical or atypical medullary carcinoma (TMC, AMC), or nonmedullary carcinoma (NMC), according to their growth patterns and cellular characteristics. Results showed that only nine of the 30 cases originally diagnosed as medullary carcinoma actually fit the criteria for TMC. Seven were reclassified as AMC, and 14 as NMC. Of the latter group, 13 were infiltrating ductal carcinomas, and one was squamous cell carcinoma. Tumors for which information regarding estrogen-receptor status was known were all negative (tumor cells can be positive or negative for their receptivity to estrogen, a female hormone). Six patients with TMC had undergone mastectomy as the only treatment. Three were alive and well after at least three years, one developed metastases, and two were lost to follow-up. The remaining three TMC patients received more aggressive treatment and were alive and well. The AMC patients in this series also received aggressive treatment, and, of the five who were followed-up, two died with metastases. Results from other studies are reviewed which show, in general, improved survival for patients with typical medullary cancer. The reasons for this are not known since, in fact, some characteristics of this kind of cancer (such as its lack of estrogen receptors) are usually associated with a poorer prognosis. In summary, medullary cancer appears to be overdiagnosed, a situation that should be kept in mind by the physician when diagnosis is made. (Consumer Summary produced by Reliance Medical Information, Inc.)